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Abstract
Background: GP2 is the major membrane protein present in the pancreatic zymogen granule, and
is cleaved and released into the pancreatic duct along with exocrine secretions. The function of
GP2 is unknown. GP2's amino acid sequence is most similar to that of uromodulin, which is
secreted by the kidney. Recent studies have demonstrated uromodulin binding to bacterial Type 1
fimbria. The fimbriae serve as adhesins to host receptors. The present study examines whether
GP2 also shares similar binding properties to bacteria with Type 1 fimbria. Commensal and
pathogenic bacteria, including E. coli and Salmonella, express type 1 fimbria.
Methods: An in vitro binding assay was used to assay the binding of recombinant GP2 to defined
strains of E. coli that differ in their expression of Type 1 fimbria or its subunit protein, FimH. Studies
were also performed to determine whether GP2 binding is dependent on the presence of mannose
residues, which is a known determinant for FimH binding.
Results: GP2 binds E. coli that express Type 1 fimbria. Binding is dependent on GP2 glycosylation,
and specifically the presence of mannose residues.
Conclusion: GP2 binds to Type 1 fimbria, a bacterial adhesin that is commonly expressed by
members of the Enterobacteriacae family.
Background
GP2 is the major membrane protein in secretory granules
of the exocrine pancreas [1-5]. Depending on the species,
GP2's mass is 80–100 KDa and accounts for 35% of the
total zymogen granule membrane protein [5]. The GP2
nucleotide sequence contains motifs consistent with
domains for a signal sequence, DC8, EGF, ZP, and one
specifying a glycosylphosphatidylinositol linkage to the
membrane [6,1,7-9]. There are 7–10 potential asparagine-
linked glycosylation sites depending on the species (10 in
human GP2) [9]. During the secretory process, GP2 is
cleaved from the membrane and secreted into the pancre-
atic duct along with the other digestive enzymes [1,8,10].
GP2's biologic function is unknown. Hypotheses pro-
posed for GP2's function have included a role in pancre-
atic exocrine protein secretion; including the formation of
secretory granules, or the packaging and sorting of diges-
tive enzymes. An essential requirement for GP2, however,
was not found when GP2 null mice harbored no detecta-
ble anomalies in either protein secretion or pancreatic aci-
nar cell morphology [11].
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The bacteria Escherichia coli belongs to the family Entero-
bacteriacae and is responsible for a large burden of human
morbidity. Most commensal and pathogenic strains
express Type I fimbria, which is a filamentous protein pro-
jection that serves as an adhesin to host receptors, and
may be important for the colonization of specific niches
[12,13]. An essential subunit of Type I fimbria is the FimH
protein, which is located at the fimbrial tip. FimH medi-
ates binding to mannose containing host receptors.
GP2's closest homologue is uromodulin, a protein
expressed by the kidney that shows 52% identity and 67%
conservation in amino acid sequence. Uromodulin is
secreted into the urine and binds E. coli with Type 1 fim-
briae. A role in host defense has been proposed in which
uromodulin serves as a molecular decoy that prevents bac-
teria from binding to uroplakin, the host receptor in
uroepithelia [14,15]. In addition, two independent labo-
ratories have produced uromodulin null mice that showed
increase sensitivity to urinary tract infections [14,16]. In
this study, we demonstrate that GP2 binds E. coli that
express Type 1 fimbria.
Methods
Reagents
Recombinant human GP2 protein was purified from cul-
ture supernatants of stably transfected Chinese Hamster
Ovary cells as previously described[17]. In brief, the
recombinant human GP2 was produced using the first
505 amino acids. The terminal 32 amino acids (a.a. 506–
537), representing a hydrophobic domain that results in
the formation of a glycosylphosphatidylinositol linkage
to the membrane, was replaced by six histidine residues
that enabled purification of the secreted protein with
nickel-based affinity chromatography (Qiagen, Inc., Ger-
mantown, MD).
A rabbit anti-human GP2 polyclonal antibody was gener-
ated against amino acids 22–181 as previously described
[18].
Uromodulin was purified from human urine as previ-
ously described [3,19]. Bovine serum albumin and methyl
α-D-mannopyranoside were obtained from Sigma, Inc.
(St. Louis, MO). Peptide:N-glycosidase F was obtained
from New England BioLabs, Inc. (Ipswich, MA).
Bacteria Strains, Culture, and Metabolic Labeling
Bacteria strains used in this study included AAEC185,
AAEC185/pSH2, MG1655, AAEC072, KB91, NU14 and
J96. The characteristics and sources for the bacteria are
listed in Table 1. All strains were cultured in Luria-Bertani
media and supplemented with ampicillin (50 μg/ml) or
chloramphenicol (40 μg/ml) at 37°C as indicated.
Bacteria were metabolically labeled with [35S]methionine
as previously described [15]. Briefly, the bacteria were
grown in Luria-Bertani medium at 37°C for 16 h, col-
lected by centrifugation, and suspended in methionine-
and cysteine-free Dulbecco's Modified Eagle's Medium
Table 1: E. coli strains used in this study
Bacteria Characteristics Source
AAEC185 (-) Derived from E. coli K-12 strain, MM294, in which the fim operon 
is deleted. Also recA- [34].
Scott J. Hultgren, Washington Univ.
AAEC185/pSH2 The AAEC185 strain with the entire fim operon expressed from 
the pSH2 plasmid [35].
AAEC072 Derived from E. coli K-12 strain, MG1655. Deletion of fimB-H 
[34,36].
Ian Blomfield, Univ. of Kent
MG1655 Wild type E. coli K-12 (Fim+, but most cells are phased off for 
fimbrial expression
KB91 Derived from E. coli K-12 strain, MG1655, where the fim operon 
was deleted to produce AAEC191A [34]. The fimbrial M1L variant 
of FimH derived from intestinal E. coli was then expressed rom 
AAEC191A [25].
Evgeni V. Sokurenko, Univ. of Washington
Nu14 E. coli cystitis isolate that expresses the M1H variant of FimH [37]. Evgeni V. Sokurenko
Univ. of Washington
J96 E. coli serotype O4:K6:45, a uropathogenic pyelonephritis isolate 
that expresses the M1H variant of FimH and P (PapG1 and G3) 
fimbriae.
Obtained from American Type Culture Collection (ATCC).BMC Gastroenterology 2009, 9:58 http://www.biomedcentral.com/1471-230X/9/58
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(Mediatech, Inc., Manassas, VA) for 2 h at 37°C.
[35S]methionine and [35S]cysteine (10 mCi/ml, MP Bio-
medicals, Solon, OH) was added for 2 h followed by 4
washes with PBS. The bacterial radioactive specific activity
was determined by plating the bacteria on agar and deter-
mining the number of counts (cpm) per colony forming
unit (CFU). The experimental data was expressed as CFUs.
The radiolabeled bacteria were stored in 30% glycerol-PBS
at -70°C.
Bacterial Binding Assay
Ninety-six well polystyrene microtiter plates were incu-
bated with 10 μg/ml of GP2, uromodulin, or BSA protein
at room temperature for 30 min and then 4°C overnight.
Unbound protein was removed by washing with PBS fol-
lowed by a final incubation with 3% BSA in PBS to reduce
non-specific binding. Radiolabeled bacteria were then
reconstituted in PBS and 3% BSA, added to the well at 108
CFU/well, and incubated at room temperature for 2 h.
Unbound bacteria were removed by washing with PBS.
Bound bacteria were harvested with a solution of 1% SDS
and quantified with a scintillation counter. All binding
assays were performed in triplicate. Data for bacterial
binding was expressed as CFU/well.
For assays that required deglycosylated GP2 or uromodu-
lin, the protein was denatured in 0.5% SDS and 1% β-
mercaptoethanol at 100°C for 10 min followed by incu-
bation for 2 h in 0.05 M sodium phosphate buffer (pH
7.5), 2,500 units/ml P:Endoglycosidase F, 0.5% SDS, 1%
β-mercaptoethanol and 1% NP-40 at 37°C.
Competitive inhibition of bacteria binding was studied by
incubating with 1% (w/v) α-D-mannose or purified GP2
(50 μg/ml) in PBS for 2 h at 37°C.
Statistics
Data are expressed as the mean ± standard deviation (SD).
The student's t test was used to assess significance. A p <
0.05 was considered statistically significant.
Results
GP2 binds E. coli with FimH containing Type 1 fimbriae
Recombinant GP2 was purified from Chinese Hamster
Ovary cells that were stably transfected with cDNA encod-
ing the human GP2 gene. Subsequent analysis with gel
electrophoresis revealed a dominant band at the expected
size of 98 kDa and two small fragments at 64 kDa and 16
kDa (Figure 1A). Mass spectroscopy established that the
64 kDa was a degraded product of GP2 and the 16 kDa
band is soybean trypsin inhibitor, which was added dur-
ing the purification (data not shown). The purified GP2
retained antigenicity when probed with anti-human GP2
antibodies on immunoblots.
GP2 binding to bacteria with Type 1 fimbria Figure 1
GP2 binding to bacteria with Type 1 fimbria. Silver 
stain of SDS-PAGE (a) and protein immunoblotting (b) of 
purified recombinant human GP2 protein. Protein immunob-
lotting was performed with rabbit anti-human GP2 antisera. 
SBTI, soybean trypsin inhibitor. (B) Binding assay of bacteria 
with (AAEC185/pSH2) and without (AAEC185) Type 1 fim-
bria performed in microtiter plates coated with 1 μg/well of 
GP2, uromodulin, or BSA protein. ** p < 0.01 compared with 
AAEC185. (C) Microtiter wells coated with GP2 or BSA pro-
teins at concentrations of .1, .5, 1, 2 and 5 μg/ml, followed by 
incubation with AAEC185/pSH2 (1 × 108 CFU) bacteria that 
express Type 1 fimbria. All assays were performed in tripli-
cate. The CFU/well are calculated as the mean ± SD (n = 3) 
and the error bar represents 1 SD.
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An in vitro binding assay was performed to test whether
GP2 bound bacteria expressing type I fimbria that con-
tained an intact FimH protein. Microtiter plates coated
with purified GP2, human uromodulin, or BSA, were
incubated with radiolabeled bacteria. Two bacterial
strains were tested that differed only in their expression of
Type 1 fimbriae. GP2 bound Type 1 fimbria expressing
AAEC185/pSH2 bacteria and not the AAEC185 strain in
which fimbriae are absent. Uromodulin showed binding
properties similar to GP2. Type 1 fimbria expressing bac-
teria did not bind BSA (Figure 1B) or soybean trypsin
inhibitor (data not shown).
Binding of Type 1 fimbria expressing bacteria (AAEC185/
pSH2) was also examined at different plating concentra-
tions for GP2 (Figure 1C). No significant bacterial binding
to BSA was observed, whereas a dose dependent relation-
ship was observed for GP2.
Binding of Type 1 fimbria expressing bacteria to GP2 is 
specific
Two additional experiments were performed to evaluate
the specificity of GP2 binding to FimH-expressing bacte-
ria. First, GP2-coated microtiter plates were pre-incubated
with rabbit anti-GP2 sera before bacterial binding was
performed. The GP2 antisera inhibited AAEC185/pSH2
bacteria binding by 74% compared to normal sera derived
from non-immunized rabbits (Figure 2A). Second,
AAEC185/pSH2 bacteria were preincubated with purified
recombinant human GP2 (50 μg/ml) before application
to the GP2 coated plates (Figure 2B). GP2 preincubation
inhibited bacterial binding by 64% compared to preincu-
bation with BSA (p < 0.01).
GP2 associated mannose is required for binding to FimH-
expressing bacteria
FimH containing Type I fimbria serve as a lectin that binds
mannose residues [20,21]. Thus we examined whether
GP2 glycosylation was similarly required for Type I fim-
bria mediated binding. Peptide:N-glycosidase F was used
to removed asparagine-linked glycan chains from purified
GP2 and uromodulin proteins before plating in the wells
(Figure 3A). The binding of Type 1 fimbria expressing bac-
teria, AAEC185/pSH2, to deglycosylated GP2 was inhib-
ited 98% compared to intact GP2 (Figure 3B). Similar
results were obtained when uromodulin was treated in a
similar manner.
To demonstrate mannose mediated GP2 binding to bacte-
ria, AEC185/pSH2 bacteria were preincubated with 1% α-
D-mannose before application to the GP2 coated micro-
titer plates. Mannose pretreatment of the bacteria
decreased binding to GP2 or uromodulin by 98% (p <
0.01) (Figure 3C).
In the gastrointestinal tract, colonic epithelia contain
receptors for both P and Type 1 fimbria [22]. P fimbria
bind D-galactose residues. A binding assay was performed
using the J96 bacteria strain, an uropathogenic strain that
contains both Type I-FimH and P fimbria. Preincubation
of J96 bacteria with 1% α-D-mannose resulted in an 86%
decrease in J96 binding to GP2, indicating that binding is
mediated mainly by Type I fimbria (data not shown).
Specificity of GP2 binding to bacteria with Type 1 fimbria Figure 2
Specificity of GP2 binding to bacteria with Type 1 
fimbria. (A) AAEC185/pSH2 bacteria binding assay with 
microtiter wells previously coated with 100 ng of GP2 pro-
tein followed by preincubation with either rabbit anti-human 
GP2 antiserum or control preimmune serum. (B) 5 μg of 
GP2 protein was preincubated with Type 1 fimbriated bacte-
ria (AAEC185/pSH2) before application to the microtiter 
plates. Data are expressed as the mean CFU/well and the 
error bars equal 1SD. All assays were performed in triplicate. 
** p < 0.01 compared with control preimmune serum (A) or 
without GP2 preincubation (B).
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GP2 Binds to M1H and M1L variants of FimH
The FimH subunit of Type 1 fimbriae in uropathogenic
and enteropathogenic strains of E. coli are known to differ
in their respective affinities for mannose residues. FimH
in uropathogenic E. coli strains exhibit high affinity bind-
ing to mono-mannose residues, whereas enteropatho-
genic FimH possesses low affinity mono-mannose
binding. Variations in the FimH sequence account for the
different affinities [23,24]. GP2 did not bind AAEC072
bacteria in which the FimH gene was deleted, or MG1655
bacteria in which Type 1 fimbria is largely phased off (Fig-
ure 4). GP2 bound KB19, a recombinant strain that
expresses the low affinity M1L variant of FimH isolated
from the intestinal F-18 E. coli strain [25]. GP2 also bound
the Nu14 E. coli strain that expresses the high affinity M1H
variant of FimH. Last, GP2 also bound the uropathogenic
E. coli strain, J96, which expresses the M1H variant of
FimH and also P fimbriae.
Discussion and Conclusion
Among bacterially expressed adhesins, Type I fimbria is
the most common among the entire family of Enterobacte-
riaceae. Type I fimbria is also the most common adhesin
expressed by E. coli in the gastrointestinal and urinary
tracts. About 60% (30–100%) of fecal isolates express
Type 1 fimbria whereas only 20% (7–52%) express P fim-
bria [26]. Among patients septic from ascending cholangi-
tis, E. coli was cultured from 76% of the episodes, and
FimH was expressed by 88% of the E. coli isolates [27].
Thus E. coli with Type I fimbria represent a major patho-
gen in both the gastrointestinal and urogenital tracts.
Variations in the adhesive properties of Type I fimbriae are
characterized by either high (M1H) or low (M1L) affinity
mannose binding, which may specify differences in host
GP2 binding to bacteria with M1H and M1L Type 1 fimbriae Figure 4
GP2 binding to bacteria with M1H and M1L Type 1 
fimbriae. Different bacteria strains were tested for the abil-
ity to bind GP2 in the microtiter well binding assay. 1 × 108 
CFU/well bacteria were used for each assay. FimH designates 
bacteria with or without FimH containing Type 1 fimbria. 
Bound bacteria were expressed as the mean CFU/well and 
the error bar represents 1SD (n = 3). ** p < 0.01 compared 
to BSA.
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GP2 glycosylation with mannose residues is required for bac- teria binding Figure 3
GP2 glycosylation with mannose residues is required 
for bacteria binding. (A) SDS-PAGE of GP2 and uromodu-
lin (UMOD) proteins with (+) and without (-) deglycosylation 
with peptide:N-glycosidase F treatment. (B) Binding of Type 
1 fimbriated bacteria (AAEC185/pSH2) to glycosylated and 
deglycosylated GP2 or UMOD. (C) AAEC185/pSH2 bacteria 
binding to GP2 after pre-incubation with 1% (v/v) α-D-man-
nose. Data are expressed as the mean CFU/well of triplicate 
samples and the error bar represents 1SD. ** p < 0.01 com-
pared with untreated controls.
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cell binding [24,25]. Eighty percent of intestinal isolates
bind monomannosyl residues with low affinity (M1L phe-
notype) and 70% of urinary isolates bind monomannosyl
residues with high affinity (M1H phenotype) [25]; with
differences in affinity measured as high as 15-fold. In this
study, we demonstrate that GP2 is capable of binding
both M1H and M1L variants of FimH.
Uromodulin is known to self assemble into a macromo-
lecular structure and represents the major constituent of
renal casts. Once secreted, GP2 has also been described to
assemble into a fibrillar network [28]. Both GP2 and uro-
modulin contain a ZP domain that is responsible for its
polymerization in the extracellular space [29-31]. Thus
similar to uromodulin in the kidney, GP2 binding to Type
I fimbriae may serve as a physical barrier and as a molec-
ular decoy for bacterial adhesion. Although the common
bile duct and pancreatic duct share a common exit to the
intestine, ascending infections of the pancreatic duct have
not been reported in the literature and clearly are not
commonly observed in the clinical setting. In contrast,
ascending biliary tract infections secondary to bacteria
derived from the intestine are relatively common. Even
when the pancreatic duct is obstructed with protein or
stones in chronic pancreatitis, ascending infections are
not reported. It is of interest that GP2 comprises most of
the protein precipitate present in the duct of patients
afflicted with chronic pancreatitis, and thus may serve a
protective role against infection [32].
Uromodulin's role in host defense has been supported in
an animal model in which UMOD null mice expressed
more persistent infections when uropathogenic bacteria
were introduced into the urinary bladder [14]. Similar
experiments have yet to be successful in GP2 null mice,
which may be secondary to several factors. First, an ani-
mal model for ascending pancreatic duct infections has
not been established. Second, almost all investigative E.
coli strains are derived from the intestine or urogenital
tract. As observed in the intestine and urogenital tract,
numerous strains show sequence variation in FimH,
which represents an adaptation to a different host envi-
ronment. Because ascending infections of the pancreatic
duct have not been observed, bacterial strains have not
been isolated from the pancreatic duct and thus may com-
promise current efforts at defining in vivo GP2's role in
host defense. Future studies will require the isolation of
bacterial strains that thrive in the pancreatic duct. Such
bacteria may include those predisposed to the biliary
tract. Overall, the similarities between GP2 and uromod-
ulin in biochemical structure and binding to Type 1 fim-
briae support a role for GP2 in host defense.
Recent studies have also demonstrated GP2 expression by
M cells in follicle-associated epithelium of intestinal
Peyer's patches [33]. Whether GP2 binding to bacteria
expressing Type 1 fimbria serves a role in the intestinal
Peyer's patch represents a promising area for further inves-
tigation.
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